- Norway
- /
- Healthtech
- /
- OB:CARA
Carasent First Quarter 2024 Earnings: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)
Carasent (OB:CARA) First Quarter 2024 Results
Key Financial Results
- Revenue: kr66.9m (up 12% from 1Q 2023).
- Net loss: kr10.6m (loss widened by kr9.52m from 1Q 2023).
- kr0.15 loss per share (further deteriorated from kr0.01 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Carasent Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in Norway.
The company's shares are up 41% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 3 warning signs for Carasent (2 can't be ignored!) that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OB:CARA
Carasent
Provides cloud based electronic health record solutions to the health care industry in Sweden, Norway, and internationally.
Flawless balance sheet with reasonable growth potential.